Company news
Telomir Pharmaceuticals, Inc. news in 2024
Telomir Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.
Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease
December 22, 2024
Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation
December 16, 2024
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price
December 11, 2024
Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1
December 2, 2024
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
November 20, 2024
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo, to Lead IND and INAD Applications for Human and Veterinary Indications
September 5, 2024
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications
September 3, 2024
Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman
August 11, 2024
Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes
July 1, 2024
Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1
May 29, 2024
Telomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support
May 15, 2024
Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.
April 15, 2024
Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
March 25, 2024
Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th
March 21, 2024
Telomir Pharmaceuticals Announces Closing of Initial Public Offering
February 12, 2024
Decks in 2024
- Investor Presentation (August 2024)
Investor deck · 27 slides · August 2024
- Corporate Update (April 2024)
Corporate update · 31 slides · Apr 15, 2024